Bladder & Kidney Cancer
Bladder & Kidney Cancer: Personalized Oncology Treatment
At the Nagourney Cancer Institute, we believe every cancer patient deserves a treatment plan tailored to their unique biology.
Understanding Bladder and Kidney Cancer
Bladder and kidney cancers are complex diseases characterized by diverse genetic and environmental factors. Our research, led by Dr. Robert Nagourney, emphasizes a personalized approach to treatment – one that goes beyond standard protocols.
​
According to the American Cancer Society, recent studies indicate that bladder cancer accounts for approximately 83,000 new cases and 17,000 deaths annually in the United States, while kidney cancer shows a rising trend with significant impacts on patient survival. These statistics highlight the urgent need for advanced, personalized treatment strategies.
​
In-Depth Analysis: Our state-of-the-art Functional Profiling test examines how your unique cancer cells respond to various therapies.
Targeted Therapy: Benefit from treatment recommendations that are precisely matched to your cancer’s characteristics.
Hope for Survival: Particularly for patients with inoperable or treatment-resistant cancers, our personalized plan may open up new avenues.
​
KidneY
Cancer
​
Kidney cancers—known as renal cell carcinomas—arise within the body of the kidney, not the collecting system. According to the American Cancer Society (ACS), more than 60,000 people in the United States are diagnosed with kidney cancer annually.
​
Most of these tumors are known as clear cell carcinomas, which over-produce proteins associated with the formation of blood vessels. It is now known that a mutation in the Von Hippel Lindau (VHL) gene is responsible for most of these cancers. Less common forms include papillary (both familial and non-familial) and chromophobe tumors.
Stage 4 Kidney Patient Story
After three months of conventional treatment for metastatic kidney cancer at Stanford, where he was surrounded by colleagues, he was not responding to therapy.
​
He stopped producing red blood cells. He checked out of the hospital and was driven to Rational Therapeutics (now Nagourney Cancer Institute), where he arranged to have a lymph node removed for a functional profiling assay.
​
The test, or “FUNCTIONAL PROFILE” of my tumor, led to a recommendation for a combination of three conventional anti-cancer drugs. However, none are drugs of choice for kidney cancer; none of them would have been used as “standard” therapy.
​
— John Friedberg, MD
The Role of Functional Profiling
Functional Profiling is a breakthrough diagnostic tool that assesses the effectiveness of multiple treatment options on a patient’s cancer cells. Peer-reviewed studies support its use, and numerous survivor stories underscore the potential of this approach. Whether you are newly diagnosed or have exhausted conventional therapies, Functional Profiling can guide you towards a more hopeful path.
​
Why Choose Nagourney Cancer Institute?
Dr. Robert Nagourney, a triple board-certified MD and oncologist, brings decades of expertise in cancer research and treatment. Our mission is to offer patients individualized care that significantly increases the chances of success, especially when standard treatments have failed.
​
Your consultation is the first step towards better outcomes. Explore our innovative approach and learn how we can help you discover a treatment plan uniquely designed for you.
​
Bladder Cancer Treatment
​
​
Almost 75 percent of people with bladder cancer have a non-invasive form and can be treated with either surgery or radiation.
In more advanced cases, chemotherapy is administered to prevent recurrence or control metastatic disease.
The drugs with activity in bladder cancer include cisplatin and carboplatin, doxorubicin, Mitomycin-C, 5 FU, cytoxan, interferon, Taxol, and gemcitabine.
​
The activity of immunotherapy for this disease has added a new dimension to the treatment of this disease with some patients responding to the PD-1, PDL-1 checkpoint inhibitors.
​
Also, good activity is seen with many drug combinations.
When bladder tumors are removed, we can study them in our laboratory to examine the activity of each of the drugs and combinations of interest.
Kidney Cancer Treatment
​
Discovered early, kidney cancer can be cured with surgery. A patient may have an entire kidney removed (the body can function effectively with only one kidney) or may undergo nephron-sparing surgery for partial kidney removal.
​
As ACS points out, kidney cancer cells are usually resistant to chemotherapy. Nonetheless, some chemotherapeutic agents (such as vinblastine, floxuridine, 5-fluorouracil (5-FU), and capecitabine) have been shown to help in a small number of patients.
​
The development of newer classes of drugs known as the VEGF antagonists includes the monoclonal antibody Bevacizumab and small molecule drugs like Sunitinib, Sorafenib, Axitinib, Pazopanib, and Cabozantinib. In addition, the mTOR inhibitors can offer benefit to a growing number of patients with this disease.
​
Immunotherapy has revolutionized the management of kidney cancer with good and sometimes durable responses seen with the same checkpoint inhibitors that are used in bladder cancer. Many of these agents used in these diseases can be tested in our laboratory by Ex-Vivo Analysis of Programmed Cell Death (our EVA-PCD assay) to determine efficacy and combination effects.
Call us at 800-542-4357 or email us via our Contact Us page to find out how we can test your cancer cells which enables us to identify those drugs and combinations most likely to be effective for treating your bladder or kidney cancer.